Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

MediWound (MDWD) EBIT (2016 - 2025)

MediWound has reported EBIT over the past 13 years, most recently at -$7.8 million for Q4 2025.

  • For Q4 2025, EBIT fell 27.85% year-over-year to -$7.8 million; the TTM value through Dec 2025 reached -$25.3 million, down 30.24%, while the annual FY2025 figure was -$25.3 million, 30.24% down from the prior year.
  • EBIT for Q4 2025 was -$7.8 million at MediWound, down from -$6.5 million in the prior quarter.
  • Over five years, EBIT peaked at $2.1 million in Q4 2022 and troughed at -$7.8 million in Q4 2025.
  • A 5-year average of -$4.0 million and a median of -$3.8 million in 2023 define the central range for EBIT.
  • Biggest five-year swings in EBIT: skyrocketed 160.3% in 2022 and later crashed 283.42% in 2023.
  • Year by year, EBIT stood at -$3.5 million in 2021, then skyrocketed by 160.3% to $2.1 million in 2022, then crashed by 283.42% to -$3.9 million in 2023, then tumbled by 56.68% to -$6.1 million in 2024, then decreased by 27.85% to -$7.8 million in 2025.
  • Business Quant data shows EBIT for MDWD at -$7.8 million in Q4 2025, -$6.5 million in Q3 2025, and -$5.7 million in Q2 2025.